Literature DB >> 9811899

Hybrid Ty1/HIV-1 elements used to detect inhibitors and monitor the activity of HIV-1 reverse transcriptase.

D V Nissley1, P L Boyer, D J Garfinkel, S H Hughes, J N Strathern.   

Abstract

We previously demonstrated that hybrid retrotransposons composed of the yeast Ty1 element and the reverse transcriptase (RT) of HIV-1 are active in the yeast Saccharomyces cerevisiae. The RT activity of these hybrid Ty1/HIV-1 (his3AI/AIDS RT; HART) elements can be monitored by using a simple genetic assay. HART element reverse transcription depends on both the polymerase and RNase H domains of HIV-1 RT. Here we demonstrate that the HART assay is sensitive to inhibitors of HIV-1 RT. (-)-(S)-8-Chloro-4,5,6, 7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5,1-jk][1, 4]-benzodiazepin-2(1H)-thione monohydrochloride (8 Cl-TIBO), a well characterized non-nucleoside RT inhibitor (NNRTI) of HIV-1 RT, blocks propagation of HART elements. HART elements that express NNRTI-resistant RT variants of HIV-1 are insensitive to 8 Cl-TIBO, demonstrating the specificity of inhibition in this assay. HART elements carrying NNRTI-resistant variants of HIV-1 RT can be used to identify compounds that are active against drug-resistant viruses.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9811899      PMCID: PMC24958          DOI: 10.1073/pnas.95.23.13905

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  52 in total

1.  The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1.

Authors:  D W Rodgers; S J Gamblin; B A Harris; S Ray; J S Culp; B Hellmig; D J Woolf; C Debouck; S C Harrison
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-14       Impact factor: 11.205

2.  Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors.

Authors:  J Ding; K Das; H Moereels; L Koymans; K Andries; P A Janssen; S H Hughes; E Arnold
Journal:  Nat Struct Biol       Date:  1995-05

3.  Population dynamics studies of wild-type and drug-resistant mutant HIV in mixed infections.

Authors:  M M Rayner; B Cordova; D A Jackson
Journal:  Virology       Date:  1997-09-15       Impact factor: 3.616

4.  Synthesis and biological activity of novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 2-Aryl-substituted benzimidazoles.

Authors:  T Roth; M L Morningstar; P L Boyer; S H Hughes; R W Buckheit; C J Michejda
Journal:  J Med Chem       Date:  1997-12-19       Impact factor: 7.446

5.  Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant.

Authors:  K Das; J Ding; Y Hsiou; A D Clark; H Moereels; L Koymans; K Andries; R Pauwels; P A Janssen; P L Boyer; P Clark; R H Smith; M B Kroeger Smith; C J Michejda; S H Hughes; E Arnold
Journal:  J Mol Biol       Date:  1996-12-20       Impact factor: 5.469

6.  Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity.

Authors:  S S Yang; V Fliakas-Boltz; J P Bader; R W Buckheit
Journal:  Leukemia       Date:  1995-10       Impact factor: 11.528

7.  Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors.

Authors:  K Rittinger; G Divita; R S Goody
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

8.  A screen in Escherichia coli for nucleoside analogs that target human immunodeficiency virus (HIV) reverse transcriptase: coexpression of HIV reverse transcriptase and herpes simplex virus thymidine kinase.

Authors:  B Kim; L A Loeb
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

9.  Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8 A resolution.

Authors:  J Ding; K Das; C Tantillo; W Zhang; A D Clark; S Jessen; X Lu; Y Hsiou; A Jacobo-Molina; K Andries
Journal:  Structure       Date:  1995-04-15       Impact factor: 5.006

10.  Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors.

Authors:  R A Spence; W M Kati; K S Anderson; K A Johnson
Journal:  Science       Date:  1995-02-17       Impact factor: 47.728

View more
  7 in total

Review 1.  Minority variants of drug-resistant HIV.

Authors:  Sara Gianella; Douglas D Richman
Journal:  J Infect Dis       Date:  2010-09-01       Impact factor: 5.226

2.  APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast.

Authors:  April J Schumacher; Dwight V Nissley; Reuben S Harris
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-06       Impact factor: 11.205

3.  Sensitive phenotypic detection of minor drug-resistant human immunodeficiency virus type 1 reverse transcriptase variants.

Authors:  Dwight V Nissley; Elias K Halvas; Nicole L Hoppman; David J Garfinkel; John W Mellors; Jeffrey N Strathern
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

4.  Targeting Tn5 transposase identifies human immunodeficiency virus type 1 inhibitors.

Authors:  Brandon Ason; Daniel J Knauss; Allison M Balke; George Merkel; Anna Marie Skalka; William S Reznikoff
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

5.  Characterization of novel non-nucleoside reverse transcriptase (RT) inhibitor resistance mutations at residues 132 and 135 in the 51 kDa subunit of HIV-1 RT.

Authors:  Dwight V Nissley; Jessica Radzio; Zandrea Ambrose; Chih-Wei Sheen; Noureddine Hamamouch; Katie L Moore; Gilda Tachedjian; Nicolas Sluis-Cremer
Journal:  Biochem J       Date:  2007-05-15       Impact factor: 3.857

Review 6.  Yeast and the AIDS virus: the odd couple.

Authors:  Marie-Line Andréola; Simon Litvak
Journal:  J Biomed Biotechnol       Date:  2012-06-17

7.  Emergence of primary NNRTI resistance mutations without antiretroviral selective pressure in a HAART-treated child.

Authors:  Elizabeth S Machado; Adriana O Afonso; Dwight V Nissley; Philippe Lemey; Silvia M Cunha; Ricardo H Oliveira; Marcelo A Soares
Journal:  PLoS One       Date:  2009-03-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.